Abstract
Hormonal contraceptive therapy (estrogens and/or progestogens) includes different formulations associated with varying venous thromboembolism (VTE) risks. The thrombogenicity of combined hormonal contraceptives (CHCs) is due at least in part to multiple changes in clotting factors and the vasculature and is dependent on both estrogen dose and type of progestin. Transdermal patch and vaginal ring users have similar or higher VTE risk as combined oral contraceptive users. Progestin-only agents have varying VTE risk. While depot medroxyprogesterone acetate appears to increase VTE risk, the levonorgestrel-based intrauterine system and low-dose progestin-only pills have no additional VTE risk. There are less data for the subdermal progestin-only implant. This article reviews contraceptive-related VTE risk by agent and by clinical scenario, including in patients with inherited thrombophilia, systemic lupus erythematosus with or without antiphospholipid antibodies or antiphospholipid syndrome, and sickle cell disease. Relevant clinical practice guidelines are reviewed. A multidisciplinary approach to counseling is needed for patient-focused decision-making.
References
1.
Jones
J
, Mosher
W
, Daniels
K.
Current contraceptive use in the United States, 2006-2010, and changes in patterns of use since 1995
. Natl Health Stat Report
. 18
October
2012
(60
):1
-15
.2.
Rotermann
M
, Dunn
S
, Black
A.
Oral contraceptive use among women aged 15 to 49: results from the Canadian Health Measures Survey
. Health Rep
. October
2015
;26
(10
):21
-28
.3.
Tchaikovski
SN
, Rosing
J.
Mechanisms of estrogen-induced venous thromboembolism
. Thromb Res
. 2010
;126
(1
):5
-11
.4.
Teal
S
, Edelman
A.
Contraception selection, effectiveness, and adverse effects: a review
. JAMA
. 2021
;326
(24
):2507
-2518
.5.
Oral Contraceptive and Hemostasis Study Group
. The effects of seven monophasic oral contraceptive regimens on hemostatic variables: conclusions from a large randomized multicenter study
. Contraception
. 2003
;67
(3
):173
-185
.6.
Sandset
PM
. Mechanisms of hormonal therapy related thrombosis
. Thromb Res
. 2013
;131
(suppl 1
):S4
-S7
.7.
Hugon-Rodin
J
, Fontana
P
, Poncet
A
, Streuli
I
, Casini
A
, Blondon
M.
Longitudinal profile of estrogen-related thrombotic biomarkers after cessation of combined hormonal contraceptives
. Blood
. 2024
;143
(1
):70
-78
.8.
Rosing
J
, Middeldorp
S
, Curvers
J
, et al. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study
. Lancet
. 1999
;354
(9195
):2036
-2040
.9.
Middeldorp
S
, Meijers
JC
, van den Ende
AE
, et al. Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: a cross-over study
. Thromb Haemost
. 2000
;84
(1
):4
-8
.10.
Kemmeren
JM
, Algra
A
, Meijers
JC
, et al. Effect of second- and third-generation oral contraceptives on the protein C system in the absence or presence of the factor V Leiden mutation: a randomized trial
. Blood
. 2004
;103
(3
):927
-933
.11.
Raps
M
, Helmerhorst
F
, Fleischer
K
, et al. Sex hormone-binding globulin as a marker for the thrombotic risk of hormonal contraceptives
. J Thromb Haemost
. 2012
;10
(6
):992
-997
.12.
Stegeman
BH
, Helmerhorst
FM
, Vos
HL
, Rosendaal
FR
, Van Hylckama Vlieg
A.
Sex hormone-binding globulin levels are not causally related to venous thrombosis risk in women not using hormonal contraceptives
. J Thromb Haemost
. 2012
;10
(10
):2061
-2067
.13.
Sitruk-Ware
RL
, Menard
J
, Rad
M
, et al. Comparison of the impact of vaginal and oral administration of combined hormonal contraceptives on hepatic proteins sensitive to estrogen
. Contraception
. 2007
;75
(6
):430
-437
.14.
Fleischer
K
, van Vliet
HA
, Rosendaal
FR
, Rosing
J
, Tchaikovski
S
, Helmerhorst
FM
. Effects of the contraceptive patch, the vaginal ring and an oral contraceptive on APC resistance and SHBG: a cross-over study
. Thromb Res
. 2009
;123
(3
):429
-435
.15.
Van Den Heuvel
MW
, Van Bragt
AJ
, Alnabawy
AK
, Kaptein
MC
. Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive
. Contraception
. 2005
;72
(3
):168
-174
.16.
Rad
M
, Kluft
C
, Ménard
J
, et al. Comparative effects of a contraceptive vaginal ring delivering a nonandrogenic progestin and continuous ethinyl estradiol and a combined oral contraceptive containing levonorgestrel on hemostasis variables
. Am J Obstet Gynecol
. 2006
;195
(1
):72
-77
.17.
Kluft
C
, Meijer
P
, LaGuardia
KD
, Fisher
AC
. Comparison of a transdermal contraceptive patch vs. oral contraceptives on hemostasis variables
. Contraception
. 2008
;77
(2
):77
-83
.18.
Johnson
JV
, Lowell
J
, Badger
GJ
, Rosing
J
, Tchaikovski
S
, Cushman
M.
Effects of oral and transdermal hormonal contraception on vascular risk markers: a randomized controlled trial
. Obstet Gynecol
. 2008
;111
(suppl 2, pt 1
):278
-284
.19.
Lindqvist
PG
, Rosing
J
, Malmquist
A
, Hillarp
A.
Etonogestrel implant use is not related to hypercoagulable changes in anticoagulant system
. J Thromb Haemost
. 2003
;1
(3
):601
-602
.20.
Van Vliet
HA
, Tchaikovski
SN
, Rosendaal
FR
, Rosing
J
, Helmerhorst
FM
. The effect of the levonorgestrel-releasing intrauterine system on the resistance to activated protein C (APC)
. Thromb Haemost
. 2009
;101
(4
):691
-695
.21.
Shaaban
MM
, Elwan
SI
, El-Kabsh
MY
, Farghaly
SA
, Thabet
N.
Effect of levonorgestrel contraceptive implants, norplant, on blood coagulation
. Contraception
. 1984
;30
(5
):421
-430
.22.
Viegas
OA
, Koh
SC
, Ratnam
SS
. The effects of reformulated 2-rod norplant implant on hemostasis after three years
. Contraception
. 1996
;54
(4
):219
-228
.23.
Brito
MB
, Ferriani
RA
, Meijers
JC
, et al. Effects of the etonogestrel- releasing contraceptive implant inserted immediately postpartum on maternal hemostasis: a randomized controlled trial
. Thromb Res
. 2012
; 130
(3
):355
-360
.24.
Egberg
N
, Van Beek
A
, Gunnervik
C
, et al. Effects on the hemostatic system and liver function in relation to implanon and norplant. A prospective randomized clinical trial
. Contraception
. 1998
;58
(2
):93
-98
.25.
Vieira
CS
, Ferriani
RA
, Garcia
AA
, et al. Use of the etonogestrel-releasing implant is associated with hypoactivation of the coagulation cascade
. Hum Reprod
. 2007
;22
(8
):2196
-2201
.26.
Fahmy
K
, Khairy
M
, Allam
G
, Gobran
F
, Alloush
M.
Effect of depo-medroxyprogesterone acetate on coagulation factors and serum lipids in Egyptian women
. Contraception
. 1991
;44
(4
):431
-444
.27.
Goldstein
J
, Cushman
M
, Badger
GJ
, Johnson
JV
. Effect of depomedroxyprogesterone acetate on coagulation parameter: a pilot study
. Fertil Steril
. 2007
;87
(6
):1267
-1270
.28.
Kawano
H
, Motoyama
T
, Hirai
N
, et al. Effect of medroxyprogesterone acetate plus estradiol on endothelium-dependent vasodilation in postmenopausal women
. Am J Cardiol
. 2001
;87
(2
):238
-240
.29.
Lidegaard
O
, Nielsen
LH
, Skovlund
CW
, Skjeldestad
FE
, Løkkegaard
E.
Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9
. BMJ
. 25
October
2011
;343
:d6423
.30.
Samuelsson
E
, Hägg
S.
Incidence of venous thromboembolism in young Swedish women and possibly preventable cases among combined oral contraceptive users
. Acta Obstet Gynecol Scand
. 2004
;83
(7
):674
-681
.31.
Stegeman
BH
, de Bastos
M
, Rosendaal
FR
, et al. Different combined oral contraceptives and the risk of venous thrombosis: systematic review and network meta-analysis
. BMJ
. 12
September
2013
;347
:f5298
.32.
de Bastos
M
, Stegeman
BH
, Rosendaal
FR
, et al. Combined oral contraceptives: venous thrombosis
. Cochrane Database Syst Rev
. 2014
;2014
(3
): CD010813
.33.
Lidegaard
Ø
, Edström
B
, Kreiner
S.
Oral contraceptives and venous thromboembolism: a five-year national case-control study
. Contraception
. 2002
;65
(3
):187
-196
.34.
Bergendal
A
, Persson
I
, Odeberg
J
, et al. Association of venous thromboembolism with hormonal contraception and thrombophilic genotypes
. Obstet Gynecol
. 2014
;124
(3
):600
-609
.35.
Lidegaard
O
, Nielsen
LH
, Skovlund
CW
, Løkkegaard
E.
Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001-10
. BMJ
. 10
May
2012
;344
:e2990
.36.
Tepper
NK
, Dragoman
MV
, Gaffield
ME
, Curtis
KM
. Nonoral combined hormonal contraceptives and thromboembolism: a systematic review
. Contraception
. 2017
;95
(2
):130
-139
.37.
Mantha
S
, Karp
R
, Raghavan
V
, Terrin
N
, Bauer
KA
, Zwicker
JI
. Assessing the risk of venous thromboembolic events in women taking progestin-only contraception: a meta-analysis
. BMJ
. 7
August
2012
;345
:e4944
.38.
Tepper
NK
, Whiteman
MK
, Marchbanks
PA
, James
AH
, Curtis
KM
. Progestin- only contraception and thromboembolism: a systematic review
. Contraception
. 2016
;94
(6
):678
-700
.39.
Palacios
S
, Regidor
PA
, Colli
E
, et al. Oestrogen-free oral contraception with a 4 mg drospirenone-only pill: new data and a review of the literature
. Eur J Contracept Reprod Health Care
. 2020
;25
(3
):221
-227
.40.
Vasilakis
C
, Jick
H
, del Mar Melero-Montes
M.
Risk of idiopathic venous thromboembolism in users of progestagens alone
. Lancet
. 1999
;354
(9190
):1610
-1611
.41.
Poulter
NR
, Chang
CL
, Farley
TM
, Meirik
O.
Risk of cardiovascular diseases associated with oral progestagen preparations with therapeutic indications
. Lancet
. 1999
;354
(9190
):1610
.42.
Floyd
JL
, Beasley
AD
, Swaim
LS
, Turrentine
MA
, Nijjar
JB
. Association of Immediate postpartum etonogestrel implant insertion and venous thromboembolism
. Obstet Gynecol
. 2020
;135
(6
):1275
-1280
.43.
Skeith
L
, Le Gal
G
, Rodger
MA
. Oral contraceptives and hormone replacement therapy: how strong a risk factor for venous thromboembolism?
Thromb Res
. June
2021
;202
:134
-138
.44.
Conard
J
, Plu-Bureau
G
, Bahi
N
, Horellou
MH
, Pelissier
C
, Thalabard
JC
. Progestogen-only contraception in women at high risk of venous thromboembolism
. Contraception
. 2004
;70
(6
):437
-441
.45.
Van Vlijmen
EF
, Wiewel-Verschueren
S
, Monster
TB
, Meijer
K.
Combined oral contraceptives, thrombophilia and the risk of venous thromboembolism: a systematic review and meta-analysis
. J Thromb Haemost
. 2016
;14
(7
):1393
-1403
.46.
Cohen
MK
, Houry
D
, Posner
SF
. U.S. medical eligibility criteria for contraceptive use, 2024
. MMWR Recomm Rep
. 2024
;73
:1
-127
.47.
Vlijmen
EFW Van
, Veeger
NJGM
, Middeldorp
S
, et al. Thrombotic risk during oral contraceptive use and pregnancy in women with factor V Leiden or prothrombin mutation: a rational approach to contraception
. Blood
. 2011
;118
(8
):2055
-2061
.48.
Middeldorp
S
, Nieuwlaat
R
, Baumann Kreuziger
L
, et al. American Society of Hematology 2023 guidelines for management of venous thromboembolism: thrombophilia testing
. Blood Adv
. 2023
;7
(22
):7101
-7138
.49.
Sonnevi
K
, Bergendal
A
, Adami
J
, Lärfars
G
, Kieler
H.
Self-reported family history in estimating the risk of hormone, surgery and cast related VTE in women
. Thromb Res
. 2013
;132
(2
):164
-169
.50.
Middeldorp
S.
Is thrombophilia testing useful?
Hematology Am Soc Hematol Educ Program
. 2011
;2011
(1
):150
-155
.51.
Andreoli
L
, Bertsias
GK
, Agmon-Levin
N
, et al. EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome
. Ann Rheum Dis
. 2017
;76
(3
):476
-485
.52.
Petri
M
, Kim
MY
, Kalunian
KC
, et al. Combined oral contraceptives in women with systemic lupus erythematosus for the OC-SELENA trial
. N Engl J Med
. 2005
;353
(24
): 2550
-2558
.53.
Sánchez-Guerrero
J
, Uribe
AG
, Jiménez-Santana
L
, et al. A trial of contraceptive methods in women with systemic lupus erythematosus
. N Engl J Med
. 2005
;353
(24
): 2539
-2549
.54.
Barbhaiya
M
, Zuily
S
, Naden
R
, et al; ACR/EULAR APS Classification Criteria Collaborators
. 2023 ACR/EULAR antiphospholipid syndrome classification criteria
. Ann Rheum Dis
. 2023
;82
(10
):1258
-1270
.55.
Urbanus
RT
, Siegerink
B
, Roest
M
, Rosendaal
FR
, de Groot
PG
, Algra
A.
Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study
. Lancet Neurol
. 2009
;8
(11
):998
-1005
.56.
Ogunsile
FJ
, Naik
R
, Lanzkron
S.
Overcoming challenges of venous thromboembolism in sickle cell disease treatment
. Expert Rev Hematol
. 2019
;12
(3
):173
-182
.57.
Pecker
LH
, Burke
A
, Streiff
MB
, Lanzkron
S
, Naik
RP
. Progestin-only contraception is first line for sickle cell disease: a comment on “Hormonal Therapies in Females with Blood Disorders: Thrombophilia, Thrombosis, Hemoglobinopathies, and Anemias
.” Res Pract Thromb Haemost
. 2023
;7
(6
):102183
.58.
Pecker
LH
, Hussain
S
, Lanzkron
S
, et al. Women with sickle cell disease report low knowledge and use of long acting reversible contraception
. J Natl Med Assoc
. 2021
;113
(5
):552
-559
.59.
Haddad
LB
, Curtis
KM
, Legardy-Williams
JK
, Cwiak
C
, Jamieson
DJ
. Contraception for individuals with sickle cell disease: a systematic review of the literature
. Contraception
. 2012
;85
(6
):527
-537
.60.
Austin
H
, Lally
C
, Benson
JM
, Whitsett
C
, Hooper
WC
, Key
NS
. Hormonal contraception, sickle cell trait, and risk for venous thromboembolism among African American women
. Am J Obstet Gynecol
. 2009
;200
(6
):620.e1-e3
.61.
National Heart, Blood, and Lung Institute
. Evidence-based management of sickle cell disease: expert panel report
. Accessed 11
August
2024
. https://www.nhlbi.nih.gov/sites/default/files/media/docs/Evd-Bsd_SickleCellDis_Rep2014.pdf.62.
Oteng-Ntim
E
, Pavord
S
, Howard
R
, et al. Management of sickle cell disease in pregnancy. A British Society for Haematology Guideline
. Br J Haematol
. 2021
;194
(6
):980
-995
.63.
Næss
IA
, Christiansen
SC
, Romundstad
P
, Cannegieter
SC
, Rosendaal
FR
, Hammerstrøm
J.
Incidence and mortality of venous thrombosis: a population-based study
. J Thromb Haemost
. 2007
;5
(4
):692
-699
.64.
Bucciarelli
P
, Rosendaal
FR
, Tripodi
A
, et al. Risk of venous thromboembolism and clinical manifestations in carriers of antithrombin, protein C, protein S deficiency, or activated protein C resistance: a multicenter collaborative family study
. Arterioscler Thromb Vasc Biol
. 1999
;19
(4
): 1026
-1033
.65.
Mustonen
P
, Lehtonen
KV
, Javela
K
, Puurunen
M.
Persistent antiphospholipid antibody (aPL) in asymptomatic carriers as a risk factor for future thrombotic events: a nationwide prospective study
. Lupus
. 2014
;23
(14
):1468
-1476
.66.
Ahmadzadeh
Y
, Andrade
D
, Tektonidou
M
, et al. First and recurrent thrombosis risk after 3842 patient-years of follow-up: prospective results from antiphospholipid syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Clinical Database and Repository
. Abstract presented at: ACR Convergence 2021; 6
November
2021
; Poster session A.67.
Pengo
V
, Testa
S
, Martinelli
I
, et al. Incidence of a first thromboembolic event in carriers of isolated lupus anticoagulant
. Thromb Res
. 2015
;135
(1
):46
-49
.68.
Pengo
V
, Ruffatti
A
, Legnani
C
, et al. Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study
. Blood
. 2011
;118
(17
):4714
-4719
.69.
Folsom
AR
, Tang
W
, Roetker
NS
, et al. Prospective study of sickle cell trait and venous thromboembolism incidence
. J Thromb Haemost
. 2015
;13
(1
): 2
-9
.70.
Naik
RP
, Streiff
MB
, Haywood
C
, Segal
JB
, Lanzkron
S.
Venous thromboembolism incidence in the cooperative study of sickle cell disease
. J Thromb Haemost
. 2014
;12
(12
):2010
-2016
.Copyright © 2024 by The American Society of Hematology
2024
You do not currently have access to this content.
